Trial ID or NCT#



recruiting iconRECRUITING


Gastroentero-pancreatic neuroendocrine tumors (GEP-NETs) are a heterogenous group of neoplasms that arise from enterochromaffin cells of the gastrointestinal (GI) tract and pancreas. They account for 50-70% of all incident NETs. Due to the lack of symptoms in the early stage of disease and the frequency of nonspecific GI symptoms, GEP-NETs are difficult to diagnose. Identification of effective biomarkers (such as Chromogranin A) to improve GEP-NET diagnosis, as well as to assess treatment efficacy, relapse and prognosis, is important for improving outcomes for patients with GEP-NETs. The purpose of this study is to validate the performance of Brahms (BRAHMS) Chromogranin A II Kryptor (KRYPTOR) assay to monitor the course of disease in patients with well-defined GEP-NETs.

Official Title

Chromogranin A as Surveillance Biomarker in Patients With cARcinoids (The CASPAR Study)

Eligibility Criteria

Ages Eligible for Study: 18 Years to 85 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No


Pamela L. Kunz
Pamela L. Kunz
Medical oncologist
Run Zhang Shi
Clinical Associate Professor, Pathology

Contact us to find out if this trial is right for you.


Kathleen Hornbacker
(650) 721-4108